Dover has entered into a definitive settlement to acquire Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and management devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s products will expand Dover’s biopharma single-use production providing, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income during the full 12 months 2022.
When เกจ์อาร์กอนsumo closes, Malema will turn into a part of the PSG business unit inside Dover’s Pumps & Process Solutions segment.
“We see an incredible long-term growth alternative in the bioprocessing trade pushed by a strong and rising pipeline of effective novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of more efficient single-use production processes helps a sturdy outlook for our choices of single-use parts to end-customers. We believe that pairing Malema’s know-how with our current portfolio of single-use pumps for biopharma processing will greatly improve the accuracy and worth proposition of our solutions to our clients.”
“We are methodically building out our biopharma platform through proactive capacity additions, new product improvement, and opportunistic acquisitions of highly-attractive area of interest element applied sciences,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing know-how and additional strengthens our sensor portfolio with new proprietary expertise. In addition to engaging biopharma functions, we anticipate strong development in the semiconductor area on the capacity growth and re-shoring tailwinds.”
Share